| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, O Rixe, ... New England Journal of Medicine 356 (2), 115-124, 2007 | 7186 | 2007 |
| Sorafenib in advanced clear-cell renal-cell carcinoma B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Siebels, ... New England Journal of Medicine 356 (2), 125-134, 2007 | 6071 | 2007 |
| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5043 | 2011 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3721 | 2008 |
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, ... Journal of clinical oncology 27 (22), 3584-3590, 2009 | 2766 | 2009 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2596 | 2012 |
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik, TE Hutson, ... The Lancet 378 (9807), 1931-1939, 2011 | 2151 | 2011 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2102 | 2013 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... Cancer 116 (18), 4256-4265, 2010 | 1517 | 2010 |
| Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Staehler, ... Journal of clinical oncology 27 (20), 3312-3318, 2009 | 1371 | 2009 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1280 | 2021 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1270 | 2015 |
| RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 1204 | 2012 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1048 | 2018 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1046 | 2016 |
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial RJ Motzer, TE Hutson, H Glen, MD Michaelson, A Molina, T Eisen, ... The lancet oncology 16 (15), 1473-1482, 2015 | 1007 | 2015 |
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial RJ Motzer, B Escudier, P Tomczak, TE Hutson, MD Michaelson, S Negrier, ... The Lancet Oncology 14 (6), 552-562, 2013 | 847 | 2013 |
| Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma B Escudier, C Szczylik, TE Hutson, T Demkow, M Staehler, F Rolland, ... Journal of clinical oncology 27 (8), 1280-1289, 2009 | 625 | 2009 |
| Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... Journal of clinical oncology 29 (17), 2432-2438, 2011 | 620 | 2011 |
| Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial RJ Motzer, D Nosov, T Eisen, I Bondarenko, V Lesovoy, O Lipatov, ... Journal of clinical oncology 31 (30), 3791-3799, 2013 | 578 | 2013 |
